We found that the co-occurrence of TET2 and IDH2 mutations conferred a better PFS, compared with TET2 alone mutation, which also highlighting the importance of epigenetic modifications in PTCL patients. This evidence concerns the gene IDH2 and mature T-cell and NK-cell non-Hodgkin lymphoma.